Evidence map›Paper›PMID 33210576›Full record

ReviewJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2021

Cerebrovascular and neurological perspectives on adrenoceptor and calcium channel modulating pharmacotherapies.

Michael M Gezalian, Luigi Mangiacotti, Padmesh Rajput, Nicklaus Sparrow, Konrad Schlick, Shouri Lahiri

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. αImmunologic research · 2025
    Article
  4. Acute isometric and dynamic exercise do not alter cerebral sympathetic nerve activity in healthy humans.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Michael M GezalianDepartments of Neurology and Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0003-3466-2814
Luigi MangiacottiDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Padmesh RajputDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Nicklaus SparrowDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Konrad SchlickDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-8772-0857
Shouri LahiriDepartments of Neurology, Neurosurgery, and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-5469-6467
Cedars-Sinai Medical Center · US

Funding

Neuropathology of Cognitive Impairment in Critical IllnessR03AG064106 · NIA · CEDARS-SINAI MEDICAL CENTER · PI LAHIRI, SHOURI · 2019 to 2020
$255k
NIA NIH HHS R03 AG064106
6 · The paper itself

Abstract

Adrenoceptor and calcium channel modulating medications are widely used in clinical practice for acute neurological and systemic conditions. It is generally assumed that the cerebrovascular effects of these drugs mirror that of their systemic effects - and this is reflected in how these medications are currently used in clinical practice. However, recent research suggests that there are distinct cerebrovascular-specific effects of these medications that are related to the unique characteristics of the cerebrovascular anatomy including the regional heterogeneity in density and distribution of adrenoceptor subtypes and calcium channels along the cerebrovasculature. In this review, we critically evaluate existing basic science and clinical research to discuss known and putative interactions between adrenoceptor and calcium channel modulating pharmacotherapies, the neurovascular unit, and cerebrovascular anatomy. In doing so, we provide a rationale for selecting vasoactive medications based on lesion location and lay a foundation for future investigations that will define neuroprotective paradigms of adrenoceptor and calcium channel modulating therapies to improve neurological outcomes in acute neurological and systemic disorders.

Indexed as

Adrenergic AgentsAnimalsCalcium Channel BlockersCalcium ChannelsCerebrovascular DisordersHumansNervous System DiseasesReceptors, AdrenergicVasoconstrictor AgentsAdrenergic AgentsCalcium Channel BlockersCalcium ChannelsReceptors, AdrenergicVasoconstrictor AgentsAdrenergic receptorscalcium channelcalcium channel blockerneurovascular unitvasopressor

Identifiers

PMID33210576
PMCPMC7983505
OpenAlexW3098802984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.